NRXP
NRx Pharmaceuticals, Inc. [NRXP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NRXP Stock Summary
Top 10 Correlated ETFs
NRXP
Top 10 Correlated Stocks
NRXP
In the News
NRXP Financial details
Company Rating
-
Market Cap
49M
Income
-31.75M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
14 May 2024
P/E
-1.05
Forward P/E
-
PEG
0.54
P/S
-
P/B
-5.61
P/C
-
P/FCF
-1.35
Quick Ratio
0.46
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.44
EPS next Y
-
EPS next Q
-
EPS this Y
637.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-30.27%
-
-
-
-
SMA20
33.33%
SMA50
-
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
-253%
ROE
6977%
ROC
5.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.21-12.0
52W High
-71.13%
52W Low
+73.25%
RSI
50
Rel Volume
0.81
Avg Volume
172.16K
Volume
138.67K
Perf Week
-2.67%
Perf Month
-22.31%
Perf Quarter
88.32%
Perf Half Y
42.01%
-
-
-
-
Beta
0.988
-
-
Volatility
0.08%, 0.29%
Prev Close
-0.43%
Price
3.465
Change
-1.56%
Company Profile
- Volume Average 172.16K
- Market Capitalization 49M
- Employee 2
- CEO Mr. Stephen H. Willard Esq.
- Headquarters Wilmington,DE,US
- IPO Date 2017-12-04
-
Website
https://www.nrxpharma.com 
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
